 Connection
Natalie Nokoff to Glucocorticoids
This is a "connection" page, showing publications Natalie Nokoff has written about Glucocorticoids.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.031 |
|
|
|
-
Nokoff NJ, Fechner PY, Kim MS, Marshall I, Merke DP, Sarafoglou K, Hartzell AL, Lin VH, Thornton P. Glucocorticoid reduction after starting crinecerfont in pediatric patients with classic congenital adrenal hyperplasia: practical perspectives. J Clin Endocrinol Metab. 2026 Jul 15; 111(8):e1937-e1950.
Score: 0.715
-
Nokoff NJ, Buchanan C, Barker JM. Clinical Manifestations and Treatment Challenges in Infants and Children With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. J Clin Endocrinol Metab. 2025 Jan 21; 110(Supplement_1):S13-S24.
Score: 0.161
-
Sarafoglou K, Kim MS, Lodish M, Felner EI, Martinerie L, Nokoff NJ, Clemente M, Fechner PY, Vogiatzi MG, Speiser PW, Auchus RJ, Rosales GBG, Roberts E, Jeha GS, Farber RH, Chan JL. Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia. N Engl J Med. 2024 08 08; 391(6):493-503.
Score: 0.154
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|